We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

KRRO Korro Bio Inc

7.59 (18.11%)
Dec 01 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 28,334
Bid Price 36.20
Ask Price 49.00
News (1)
Day High 49.99


52 Week Range


Day Low 42.1655
Company Name Stock Ticker Symbol Market Type
Korro Bio Inc KRRO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
7.59 18.11% 49.50 20:00:00
Open Price Low Price High Price Close Price Prev Close
42.22 42.1655 49.99 49.00 41.91
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,220 28,334 $ 45.63 $ 1,292,806 - 13.00 - 54.98
Last Trade Time Type Quantity Stock Price Currency
17:17:23 15 $ 47.10 USD

Korro Bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 36.56M - - - -44.81
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Korro Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No KRRO Message Board. Create One! See More Posts on KRRO Message Board See More Message Board Posts

Historical KRRO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week37.9249.9936.1139.9219,11611.5830.54%
1 Month13.0054.9813.0039.4492,33936.50280.77%
3 Months13.0054.9813.0039.4492,33936.50280.77%
6 Months13.0054.9813.0039.4492,33936.50280.77%
1 Year13.0054.9813.0039.4492,33936.50280.77%
3 Years13.0054.9813.0039.4492,33936.50280.77%
5 Years13.0054.9813.0039.4492,33936.50280.77%

Korro Bio Description

Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to create functional tissue. Its product candidate FX-322 is being developed for treating sensorineural hearing loss.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |